These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 23417736)

  • 1. Effectiveness of paliperidone extended-release for patients with schizophrenia: focus on subjective improvement.
    Na KS; Kim CE; Kim YS; Lee JI; Han WS; Kang UG; Park DH; Kim B; Jung HY; Yoon JS; Lim SW
    Hum Psychopharmacol; 2013 Mar; 28(2):107-16. PubMed ID: 23417736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents.
    Kim EY; Chang SM; Shim JC; Joo EJ; Kim JJ; Kim YS; Ahn YM
    Curr Med Res Opin; 2013 Oct; 29(10):1231-40. PubMed ID: 23777311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.
    Kim SW; Yoon JS; Kim YS; Ahn YM; Kim CE; Go HJ; Chee IS; Jung SW; Chung YC; Kim YD; Joe S; Lee J; Kwon YJ; Yoon BH; Jae YM
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):228-35. PubMed ID: 22516251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.
    Canuso CM; Bossie CA; Amatniek J; Turkoz I; Pandina G; Cornblatt B
    Early Interv Psychiatry; 2010 Feb; 4(1):64-78. PubMed ID: 20199482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study.
    Schmauss M; Jukić V; Siracusano A; Bidzan L; Badescu GM; Maciulis V; Lahaye M; Hoeben D; Tessier C; Schreiner A
    Curr Med Res Opin; 2012 Aug; 28(8):1395-404. PubMed ID: 22746355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.
    Emsley R; Berwaerts J; Eerdekens M; Kramer M; Lane R; Lim P; Hough D; Palumbo J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):343-56. PubMed ID: 18854723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia.
    Luthringer R; Staner L; Noel N; Muzet M; Gassmann-Mayer C; Talluri K; Cleton A; Eerdekens M; Battisti WP; Palumbo JM
    Int Clin Psychopharmacol; 2007 Sep; 22(5):299-308. PubMed ID: 17690599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study.
    Gattaz WF; Campos JA; Lacerda AL; Henna E; Ruschel SI; Bressan RA; de Oliveira IR; Rocha FL; Grabowski HM; Sacomani E; Louzã MR; Quevedo J; Elkis H; Zorzetto Filho D; Périco Cde A; Lawson FL; Appolinário JC
    Curr Med Res Opin; 2014 Apr; 30(4):695-709. PubMed ID: 24289141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
    Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
    Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
    Davidson M; Emsley R; Kramer M; Ford L; Pan G; Lim P; Eerdekens M
    Schizophr Res; 2007 Jul; 93(1-3):117-30. PubMed ID: 17466492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.
    Kim SW; Chung YC; Lee YH; Lee JH; Kim SY; Bae KY; Kim JM; Shin IS; Yoon JS
    Int Clin Psychopharmacol; 2012 Sep; 27(5):267-74. PubMed ID: 22809972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.
    Kane J; Canas F; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
    Schizophr Res; 2007 Feb; 90(1-3):147-61. PubMed ID: 17092691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
    Marder SR; Kramer M; Ford L; Eerdekens E; Lim P; Eerdekens M; Lowy A
    Biol Psychiatry; 2007 Dec; 62(12):1363-70. PubMed ID: 17601495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
    Kramer M; Simpson G; Maciulis V; Kushner S; Vijapurkar U; Lim P; Eerdekens M
    J Clin Psychopharmacol; 2007 Feb; 27(1):6-14. PubMed ID: 17224706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone.
    Canuso CM; Grinspan A; Kalali A; Damaraju CV; Merriman U; Alphs L; Awad AG
    Int Clin Psychopharmacol; 2010 May; 25(3):155-64. PubMed ID: 20216424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms.
    Canuso CM; Bossie CA; Turkoz I; Alphs L
    Schizophr Res; 2009 Aug; 113(1):56-64. PubMed ID: 19560322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of paliperidone extended release on the symptoms and functioning of schizophrenia.
    Huang MW; Yang TT; Ten PR; Su PW; Wu BJ; Chan CH; Lan TH; Liu IC; Chiu WC; Li CY; Cheng KS; Yeh YC
    BMC Clin Pharmacol; 2012 Jan; 12():1. PubMed ID: 22225965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents.
    Singh J; Robb A; Vijapurkar U; Nuamah I; Hough D
    Biol Psychiatry; 2011 Dec; 70(12):1179-87. PubMed ID: 21831359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.